Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec
نویسندگان
چکیده
TVEC: Talimogene laherparepvec INTRODUCTION Inflammatory melanoma was first described in 1984 in 2 patients presenting with nodular cutaneous melanomas resected from the back followed 4 to 12 months later by recurrence in the form of diffuse, indurated, erythematous skin 20-25 cm in diameter with scattered nodularity. Microscopic examination found melanoma cells in the dermis and dermal lymphatics. Both patients died of hematogenous metastases within 6 months of their inflammatory melanoma recurrences. Although histopathologic examination of melanoma frequently finds an associated inflammatory cell infiltrate, gross clinical inflammation is extremely rare. A search of PubMed and Google Scholar performed on August 5, 2016 found 3 additional case reports of inflammatory melanoma, 2 of which involved direct dermal lymphatic extension from grossly involved lymph nodes. Here we report the first, to our knowledge, successfully treated case of surgically incurable inflammatory melanoma with emphasis on molecular and immunophenotypic characterization.
منابع مشابه
Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
BACKGROUND Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic virus talimogene laherparepvec improved durable response rate (DRR; continuous response ≥6 months) compared with subcutaneous granulocyte-macrophage colony-stimulating facto...
متن کاملTreatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% cream
IL-2: interleukin-2 INTRODUCTION The treatment of in-transit and satellite melanoma metastases is challenging. Treatment options for these cutaneous and subcutaneous lesions include surgical excision, radiotherapy, isolated limb infusion/perfusion, electrochemotherapy, cryotherapy, laser therapy (pulsed dye or carbon dioxide), systemic treatment with interferon-a or interleukin-2 (IL-2), topica...
متن کاملEfficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
OBJECTIVES Talimogene laherparepvec is the first oncolytic immunotherapy to receive approval in Europe, the USA and Australia. In the randomized, open-label Phase III OPTiM trial (NCT00769704), talimogene laherparepvec significantly improved durable response rate (DRR) versus granulocyte-macrophage colony-stimulating factor (GM-CSF) in 436 patients with unresectable stage IIIB-IVM1c melanoma. T...
متن کاملSystemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.
BACKGROUND We previously reported that talimogene laherparepvec, an oncolytic herpes virus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), resulted in an objective response rate of 26 % in patients with advanced melanoma in a phase II clinical trial. The response of individual lesions, however, was not reported. Since talimogene laherparepvec is thought to mediate anti-tumor...
متن کاملIndirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
INTRODUCTION Few randomized controlled trials have compared new treatments for metastatic melanoma. We sought to examine the relative treatment effect of talimogene laherparepvec compared with ipilimumab and vemurafenib. METHODS A systematic literature review of treatments for metastatic melanoma was undertaken but a valid network of evidence could not be established because of a lack of comp...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 3 شماره
صفحات -
تاریخ انتشار 2017